Analysts Boost Price Targets on Corcept (CORT) Following FDA Approval of Korlym
- Stocks Tank as QE Nears End, Major Fund Winds Down, and Ebola Fears
- Market Wrap: Private Employment Expands in Sept.; BofA CEO Becomes Chairman; U.S. Secret Service Director Resigns
- Bank of America (BAC) CEO Moynihan Elected as Chairman
- After-Hours Stock Movers 10/01: (RLD) (DRL) (DTV) Higher; (WILN) (NLNK) (PLTA) Lower (more...)
- Investors Yank $23.5 Billion From PIMCO in 3 Days Amid Gross Exit
Several analyst firms have revised price targets and estimates on shares of Corcept Therapeutics (Nasdaq: CORT) following news of FDA approval for its Korlym. Corcept shares last traded at $4.42, up more than 46 percent from Friday's closing price.
- JMP Securities - from $9 to $11, Market Outperform maintained
- Stifel Nicolaus - from $7 to $9, Buy maintained
- Ladenburg Thalmann - from $6 to $7, Buy maintained
You May Also Be Interested In
- Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014
- BofA/Merrill Lynch Upgrades Taseko Mines Ltd. (TGB) to Neutral (Earlier)
- Credit Suisse Starts ARAMARK Holdings (ARMK) at Outperform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesStifel Nicolaus, JMP Securities, Ladenburg Thalmann Financial Services
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!